ArticleBiotechnology and applied biochemistry2026
Enhanced Production of Astaxanthin and Zeaxanthin by Paracoccus Sp. LL1 Through Random Mutagenesis.
Article in Biotechnology and applied biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Characterization and Transcriptomic Analysis of AntarcticJournal of microbiology and biotechnology · 2026Article
- Enhanced Production of Astaxanthin and Zeaxanthin by Paracoccus Sp. LL1 Through Random Mutagenesis.Biotechnology and applied biochemistry · 2026Article
- Enhancing Astaxanthin Production inMarine drugs · 2026Article
- Advances in biomanufacturing and recent biological applications of the fundamental bacterial carotenoids: a comprehensive review.Microbial cell factories · 2025Review
- Genome sequence ofmicroPublication biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astaxanthin, a high-value carotenoid with potent antioxidant and anti-inflammatory activities, is increasingly in demand in various industries. This study reports the successful enhancement of astaxanthin and zeaxanthin production in Paracoccus sp. LL1 through random mutagenesis using ethyl methanesulfonate (EMS). To induce genetic diversity, EMS mutagenesis was employed, followed by the selection of mutants that exhibited increased carotenoid production. The top-performing mutants showed a significant 2.76-fold increase in astaxanthin and a 10.14-fold increase in zeaxanthin compared to the wild-type strain when treated with the optimal EMS concentration of 0.5%. The effects of initial glucose concentration and inoculum size on astaxanthin and zeaxanthin production were evaluated, and production was higher when glucose was 2% and inoculum size was 10%. Our findings demonstrate the potential of Paracoccus sp. LL1 as a promising alternative to traditional astaxanthin-producing organisms, such as Haematococcus pluvialis, offering advantages including faster growth, simpler cultivation requirements, and genetic tractability. This approach not only enhances carotenoid production but also highlights the novelty of using Paracoccus sp. LL1, a less-explored strain, for high-yield production of both astaxanthin and zeaxanthin. These results suggest that Paracoccus sp. LL1 could serve as an efficient platform for industrial-scale carotenoid production through metabolic engineering and random mutagenesis, providing a viable alternative to current production systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.